The Power of Personalized Medicine


by Christine Donato 

In the United States, there is no correlation between the cost of care and the quality of care. Outcomes are not tracked on a regular basis, nor are they uniformly measured.

Also alarming is that only 3 percent of cancer patients are enrolled in clinical trials, meaning 97 percent of patient data is unavailable and overlooked.

However, in recent years, the way cancer is perceived has shifted.

Instead of categorizing cancer based on the organ it affects, healthcare personnel are now categorizing cancer based on DNA mutations or markers. Not all instances of cancer have a uniquely identifiable mutation, but many do, and the amount of information about them is constantly growing.

With cancer tumor DNA analysis, doctors can compare a patient’s healthy DNA cell with that patient’s cancer DNA cell to determine the point of cancer mutation.  From there, healthcare personnel can determine if a targeted treatment exists for that particular mutation.

Adoption of Advanced Technology to Speed Adoption of Personalized Care 

With the right technology, healthcare experts can comprehend all of the data that’s underutilized in healthcare, bucketing diverse sets of patients based on ethnicity, gender, age, genome mutation, common health issues, environmental influences, and more.

With the ability to form these micro-bucket categorizations of patients, physicians can more accurately examine trends and bring this data to the point of care.

To learn more about the future of Genomics, join the upcoming free, 2-week long openSAP course, The Future of Genomics and Precision Medicine.  


  • Starting from: February 14, 2017, 9:00 UTC, open until March 15, 2017, 9:00 UTC (What does this mean?)
  • Duration: 2 weeks (2-3 hours per week), however the course is open for 4 weeks
  • Discussion forum for you to share your experiences with other learners and get the help of experts
  • Course language: English

In this course, leaders from the American Society of Clinical Oncology (ASCO) and its wholly-owned nonprofit subsidiary, CancerLinQ LLC, will help you understand precision medicine from its origins to its bright future, and show how Big Data has transformed the healthcare landscape.

Through initiatives like Ride Hard. Breathe Easy. we can raise awareness for the importance of high speed technology in healthcare as well as the importance of educating patients to demand cutting edge treatments.

Leave a Reply